Affiliation:
1. From the Department of Medicine, Center for Molecular Genetics and American Heart Association Bugher Foundation Center for Molecular Biology, University of California, San Diego, La Jolla.
Abstract
Abstract
Unraveling the pathogenesis of complex cardiovascular diseases, such as hypertension, requires the development of in vivo animal model systems. Although large-animal models have long served as the gold standard, recent advances in transgenic and gene-targeting approaches, mouse genetics, and microsurgical technology are initiating a revolution that has led to the unexpected coupling of in vivo molecular physiology with genetically engineered mice. This article discusses the design of strategies to study complex cardiovascular phenotypes in genetically modified mice, including both transgenic and gene-targeted animals. At this time, a number of strategies are used to address specific molecular or physiological questions, and examples are briefly highlighted. In addition, a number of potential problems in the generation and use of transgenic mice in the study of cardiovascular biology are presented.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference66 articles.
1. A miracle enough: the power of mice
2. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse
3. Doevendans PA Hunter JJ Lembo G Wollert KC Chien KR. Strategies for studying cardiovascular diseases in transgenic and gene-targeted mice. In: Monastersky GM Robl JM eds. Strategies in Transgenic Animal Science. Washington DC: American Society for Microbiology; 1995:107-144.
4. Chien KR. Genes and physiology: molecular physiology in genetically engineered animals. J Clin Invest. In press.
5. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献